<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>27389618</identifier>
<setSpec>1578-8989</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Alijotas-Reig, Jaume</dc:author>
<dc:author>Esteve-Valverde, Enrique</dc:author>
<dc:author>Ferrer-Oliveras, Raquel</dc:author>
<dc:description xml:lang="en">Rheumatic and systemic autoimmune diseases occur in women and, to a lesser degree, men of reproductive age. These disorders have to be clinically nonactive before conception, which is usually only possible after anti-inflammatory and immunosuppressive treatment. We must be alert since 50% of pregnancies are unplanned. Physicians should know the embryo-foetal toxicity of these drugs during pregnancy and lactation. This January 2016-updated review allows us to conclude that the majority of immunosuppressives available -anti-TNF inhibitors included- can be used before and during pregnancy, with the exception of cyclophosphamide, methotrexate, mycophenolate and leflunomide. Lactation is permitted with all drugs except methotrexate, leflunomide, mycophenolate and cyclophosphamide. Although data on abatacept, belimumab, rituximab, tocilizumab and anakinra are scant, preliminary reports agree on their safety during pregnancy and, probably, lactation. Cyclophosphamide and sulfasalazine apart, no negative effects on sperm quality, or embryo-foetal anomalies in men treated with immunosuppressives have been described.</dc:description>
<dc:type>Journal Article</dc:type>
<dc:language>es</dc:language>
<dc:subject>Lactancia</dc:subject>
<dc:subject>Efectos adversos</dc:subject>
<dc:subject>Immunosuppressive</dc:subject>
<dc:subject>Anti-inflammatory drugs</dc:subject>
<dc:subject>Lactation</dc:subject>
<dc:subject>Enfermedades autoinmunitarias</dc:subject>
<dc:subject>Adverse effects</dc:subject>
<dc:subject>Pregnancy</dc:subject>
<dc:subject>Embarazo</dc:subject>
<dc:subject>Biologics</dc:subject>
<dc:subject>Anti-TNF-α</dc:subject>
<dc:subject>Inmunodepresores</dc:subject>
<dc:subject>Autoimmune diseases</dc:subject>
<dc:subject>Biológicos</dc:subject>
<dc:subject>Antiinflammatorios</dc:subject>
<dc:date>2016 Oct 21 </dc:date>
<dc:title xml:lang="es">Tratamiento de las gestantes con enfermedades reumáticas o autoinmunitarias sistémicas con fármacos inmunodepresores y biológicos.</dc:title>
<dc:title xml:lang="en">[Treatment with immunosuppressive and biologic drugs of pregnant women with systemic rheumatic or autoimmune disease].</dc:title>
<dc:publisher>Medicina clinica</dc:publisher>
</metadata>
</record>
</pubmed-document>
